135 related articles for article (PubMed ID: 32996901)
1. A Patient with CTLA-4 Haploinsufficiency with Multiple Autoimmune Presentations: A Case Report.
Zaremehrjardi F; Baniadam L; Seif F; Arshi S; Bemanian MH; Shokri S; Rezaeifar A; Fallahpour M; Nabavi M
Iran J Immunol; 2020 Sep; 17(3):244-249. PubMed ID: 32996901
[TBL] [Abstract][Full Text] [Related]
2. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations.
Schubert D; Bode C; Kenefeck R; Hou TZ; Wing JB; Kennedy A; Bulashevska A; Petersen BS; Schäffer AA; Grüning BA; Unger S; Frede N; Baumann U; Witte T; Schmidt RE; Dueckers G; Niehues T; Seneviratne S; Kanariou M; Speckmann C; Ehl S; Rensing-Ehl A; Warnatz K; Rakhmanov M; Thimme R; Hasselblatt P; Emmerich F; Cathomen T; Backofen R; Fisch P; Seidl M; May A; Schmitt-Graeff A; Ikemizu S; Salzer U; Franke A; Sakaguchi S; Walker LSK; Sansom DM; Grimbacher B
Nat Med; 2014 Dec; 20(12):1410-1416. PubMed ID: 25329329
[TBL] [Abstract][Full Text] [Related]
3. What did we learn from CTLA-4 insufficiency on the human immune system?
Mitsuiki N; Schwab C; Grimbacher B
Immunol Rev; 2019 Jan; 287(1):33-49. PubMed ID: 30565239
[TBL] [Abstract][Full Text] [Related]
4. A Patient with CTLA-4 Haploinsufficiency Presenting Gastric Cancer.
Hayakawa S; Okada S; Tsumura M; Sakata S; Ueno Y; Imai K; Morio T; Ohara O; Chayama K; Kobayashi M
J Clin Immunol; 2016 Jan; 36(1):28-32. PubMed ID: 26644313
[TBL] [Abstract][Full Text] [Related]
5. Immune dysregulation syndrome with de novo CTLA4 germline mutation responsive to abatacept therapy.
Ureshino H; Koarada S; Kamachi K; Yoshimura M; Yokoo M; Kubota Y; Ando T; Ichinohe T; Morio T; Kimura S
Int J Hematol; 2020 Jun; 111(6):897-902. PubMed ID: 31993940
[TBL] [Abstract][Full Text] [Related]
6. Early-onset Crohn's disease and autoimmunity associated with a variant in CTLA-4.
Zeissig S; Petersen BS; Tomczak M; Melum E; Huc-Claustre E; Dougan SK; Laerdahl JK; Stade B; Forster M; Schreiber S; Weir D; Leichtner AM; Franke A; Blumberg RS
Gut; 2015 Dec; 64(12):1889-97. PubMed ID: 25367873
[TBL] [Abstract][Full Text] [Related]
7. Heterozygous
Mahat U; Ambani NM; Rotz SJ; Radhakrishnan K
Pediatr Hematol Oncol; 2021 Oct; 38(7):658-662. PubMed ID: 33900894
[TBL] [Abstract][Full Text] [Related]
8. CTLA4 Message Reflects Pathway Disruption in Monogenic Disorders and Under Therapeutic Blockade.
Garcia-Perez JE; Baxter RM; Kong DS; Tobin R; McCarter M; Routes JM; Verbsky J; Jordan MB; Dutmer CM; Hsieh EWY
Front Immunol; 2019; 10():998. PubMed ID: 31156616
[TBL] [Abstract][Full Text] [Related]
9. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4.
Kuehn HS; Ouyang W; Lo B; Deenick EK; Niemela JE; Avery DT; Schickel JN; Tran DQ; Stoddard J; Zhang Y; Frucht DM; Dumitriu B; Scheinberg P; Folio LR; Frein CA; Price S; Koh C; Heller T; Seroogy CM; Huttenlocher A; Rao VK; Su HC; Kleiner D; Notarangelo LD; Rampertaap Y; Olivier KN; McElwee J; Hughes J; Pittaluga S; Oliveira JB; Meffre E; Fleisher TA; Holland SM; Lenardo MJ; Tangye SG; Uzel G
Science; 2014 Sep; 345(6204):1623-1627. PubMed ID: 25213377
[TBL] [Abstract][Full Text] [Related]
10. Neurological manifestation of immune system dysregulation resulting from CTLA-4 receptor mutation: a case report.
Kolcava J; Litzman J; Bednarik J; Stulik J; Stourac P
Mult Scler Relat Disord; 2020 Oct; 45():102313. PubMed ID: 32623363
[TBL] [Abstract][Full Text] [Related]
11. Granulomatous interstitial nephritis with CTLA-4 haploinsufficiency: a case report.
Kohatsu K; Suzuki T; Takimoto M; Matsui K; Hashiguchi A; Koike J; Shirai S
BMC Nephrol; 2022 Nov; 23(1):367. PubMed ID: 36384506
[TBL] [Abstract][Full Text] [Related]
12. Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects.
Schwab C; Gabrysch A; Olbrich P; Patiño V; Warnatz K; Wolff D; Hoshino A; Kobayashi M; Imai K; Takagi M; Dybedal I; Haddock JA; Sansom DM; Lucena JM; Seidl M; Schmitt-Graeff A; Reiser V; Emmerich F; Frede N; Bulashevska A; Salzer U; Schubert D; Hayakawa S; Okada S; Kanariou M; Kucuk ZY; Chapdelaine H; Petruzelkova L; Sumnik Z; Sediva A; Slatter M; Arkwright PD; Cant A; Lorenz HM; Giese T; Lougaris V; Plebani A; Price C; Sullivan KE; Moutschen M; Litzman J; Freiberger T; van de Veerdonk FL; Recher M; Albert MH; Hauck F; Seneviratne S; Pachlopnik Schmid J; Kolios A; Unglik G; Klemann C; Speckmann C; Ehl S; Leichtner A; Blumberg R; Franke A; Snapper S; Zeissig S; Cunningham-Rundles C; Giulino-Roth L; Elemento O; Dückers G; Niehues T; Fronkova E; Kanderová V; Platt CD; Chou J; Chatila TA; Geha R; McDermott E; Bunn S; Kurzai M; Schulz A; Alsina L; Casals F; Deyà-Martinez A; Hambleton S; Kanegane H; Taskén K; Neth O; Grimbacher B
J Allergy Clin Immunol; 2018 Dec; 142(6):1932-1946. PubMed ID: 29729943
[TBL] [Abstract][Full Text] [Related]
13. Pitfalls of immunotherapy: lessons from a patient with CTLA-4 haploinsufficiency.
Watson LR; Slade CA; Ojaimi S; Barnes S; Fedele P; Smith P; Marum J; Lunke S; Stark Z; Hunter MF; Bryant VL; Low MSY
Allergy Asthma Clin Immunol; 2018; 14():65. PubMed ID: 30377434
[TBL] [Abstract][Full Text] [Related]
14. Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity.
Paterson AM; Lovitch SB; Sage PT; Juneja VR; Lee Y; Trombley JD; Arancibia-Cárcamo CV; Sobel RA; Rudensky AY; Kuchroo VK; Freeman GJ; Sharpe AH
J Exp Med; 2015 Sep; 212(10):1603-21. PubMed ID: 26371185
[TBL] [Abstract][Full Text] [Related]
15. Murine LRBA deficiency causes CTLA-4 deficiency in Tregs without progression to immune dysregulation.
Burnett DL; Parish IA; Masle-Farquhar E; Brink R; Goodnow CC
Immunol Cell Biol; 2017 Oct; 95(9):775-788. PubMed ID: 28611475
[TBL] [Abstract][Full Text] [Related]
16. Increased Risk for Malignancies in 131 Affected
Egg D; Schwab C; Gabrysch A; Arkwright PD; Cheesman E; Giulino-Roth L; Neth O; Snapper S; Okada S; Moutschen M; Delvenne P; Pecher AC; Wolff D; Kim YJ; Seneviratne S; Kim KM; Kang JM; Ojaimi S; McLean C; Warnatz K; Seidl M; Grimbacher B
Front Immunol; 2018; 9():2012. PubMed ID: 30250467
[No Abstract] [Full Text] [Related]
17. Clinical and Immunological Phenotype of Patients With Primary Immunodeficiency Due to Damaging Mutations in
Klemann C; Camacho-Ordonez N; Yang L; Eskandarian Z; Rojas-Restrepo JL; Frede N; Bulashevska A; Heeg M; Al-Ddafari MS; Premm J; Seidl M; Ammann S; Sherkat R; Radhakrishnan N; Warnatz K; Unger S; Kobbe R; Hüfner A; Leahy TR; Ip W; Burns SO; Fliegauf M; Grimbacher B
Front Immunol; 2019; 10():297. PubMed ID: 30941118
[TBL] [Abstract][Full Text] [Related]
18. Lessons from CTLA-4 deficiency and checkpoint inhibition.
Lo B; Abdel-Motal UM
Curr Opin Immunol; 2017 Dec; 49():14-19. PubMed ID: 28806575
[TBL] [Abstract][Full Text] [Related]
19. A de novo monoallelic CTLA-4 deletion causing pediatric onset CVID with recurrent autoimmune cytopenias and severe enteropathy.
Lougaris V; Baronio M; Gazzurelli L; Lorenzini T; Fuoti M; Moratto D; Bozzola A; Ricci C; Bondioni MP; Ravelli A; Villanacci V; Plebani A
Clin Immunol; 2018 Dec; 197():186-188. PubMed ID: 30326257
[No Abstract] [Full Text] [Related]
20. Abatacept for treatment-refractory pediatric CTLA4-haploinsufficiency.
Lanz AL; Riester M; Peters P; Schwerd T; Lurz E; Hajji MS; Rohlfs M; Ley-Zaporozhan J; Walz C; Kotlarz D; Klein C; Albert MH; Hauck F
Clin Immunol; 2021 Aug; 229():108779. PubMed ID: 34116213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
